The drug developer ValiRx (LON:VAL) has been asked to give a presentation at the prestigious American Association for Cancer Research Conference in Washington starting this Saturday (April 6).
Attended by 17,000 oncology experts, this is by far the largest of a series of events the company is using to engage with the scientific and investor communities.
It took part in a gathering called One Nucleus and a networking opportunity at the London Stock Exchange last month.
It has also showcased its activities in the capital, Oxford, Turku in Finland, Barcelona and Brussels.
ValiRx’s lead drug candidate is VAL201 for prostate cancer, and the groundwork is currently being laid to enter phase Ia clinical trials that should take place this year. This includes finding a primary and secondary site for the first-in-man study and a manufacturer of 201. The group is also finalising protocols and “associated regulatory activities”.
Separately, it said VAL101 for the regulation of rebellious genes, is at an “advanced pre-clinical stage”, having completed much of the work planned using a grant provided under the Eurostars programme.
Chief executive Satu Vainikka said: "Our technical and commercial progress over the past year has been pleasing and we are well set for the future as we look to further establish ourselves at the forefront of personalised oncology development."